hydroxychloroquine has been researched along with Glomerulonephritis, Lupus in 74 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) has been recommended as a basic treatment for lupus nephritis (LN) during this decade based on its ability to improve LN-related renal immune-mediated inflammatory lesions." | 8.12 | Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis. ( An, N; Chen, RH; Guo, Y; Huang, TS; Huang, XJ; Li, ZH; Liu, HF; Pan, QJ; Wu, HL; Wu, ZH; Xue, J; Yang, C, 2022) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 7.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 7.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "To assess the effectiveness and safety of a protocol using medium doses of prednisone to treat lupus nephritis." | 7.80 | Prednisone in lupus nephritis: how much is enough? ( Danza, A; Delgado, S; Garcia, M; Khamashta, M; Perales, I; Ruiz-Irastorza, G; Villar, I, 2014) |
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 7.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE)." | 7.30 | Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. ( Abdelnabi, HH; Dawoud, HE; El-Shahaby, WA; Elrifaey, SM; Gheet, FS, 2023) |
| "However, the effect of HCQ on UC-MSCs in lupus nephritis (LN) has not been investigated." | 5.48 | Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. ( Chen, Q; Han, X; Kuang, S; Liao, X; Luan, Y; Ma, J; Mai, S; Tian, X; Wei, Y; Wu, Y; Yang, J; Yang, Y; Zou, L, 2018) |
| " Despite these challenges, belimumab, voclosporin, and anifromulab, approved by the United States Food and Drug Administration (FDA) to treat SLE or lupus nephritis (LN), enhanced our armamentarium of traditional therapies, such as hydroxychloroquine, corticosteroids, and immunosuppressives." | 5.22 | B cell-targeted therapies in systemic lupus erythematosus. ( Arbitman, L; Furie, R; Vashistha, H, 2022) |
| " A prospective study found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus nephritis." | 4.90 | Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. ( Clowse, ME; Peart, E, 2014) |
| "A 15-year-old girl had a history of diffuse goiter and received methimazole treatment 2 months before admission to the hospital." | 4.82 | Methimazole-induced lupus erythematosus: a case report. ( Chiang, BL; Tsai, WY; Wang, LC; Yang, YH, 2003) |
| " Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (±V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure." | 4.31 | The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. ( Anders, HJ; Bruchfeld, A; Fernández-Juárez, GM; Floege, J; Frangou, E; Goumenos, D; Kronbichler, A; Loutan, J; Segelmark, M; Stevens, KI; Tesar, V; Turkmen, K; van Kooten, C, 2023) |
| "Hydroxychloroquine (HCQ) has been recommended as a basic treatment for lupus nephritis (LN) during this decade based on its ability to improve LN-related renal immune-mediated inflammatory lesions." | 4.12 | Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis. ( An, N; Chen, RH; Guo, Y; Huang, TS; Huang, XJ; Li, ZH; Liu, HF; Pan, QJ; Wu, HL; Wu, ZH; Xue, J; Yang, C, 2022) |
| "Evaluate the impact of pregnancy physiology and medication non-adherence on serum hydroxychloroquine (HCQ) pharmacokinetics (PK) and exposure-response in SLE." | 4.12 | Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Gonzalez, D; Hornik, CP; Maharaj, AR; Weiner, D, 2022) |
| " Multiple logistic analysis adjusting for body mass index (BMI), lupus nephritis, serum uric acid, and estimated glomerular filtration rate revealed HCQ treatment was associated with exceedingly lower risk of preeclampsia in SLE pregnancy (odds ratio (OR) 0." | 3.91 | Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| " Lupus flares were predicted by HCQ discontinuation, a history of lupus nephritis, high pre-pregnancy serum uric acid and low C4 levels." | 3.81 | Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. ( Ju, JH; Ko, HS; Koh, JH; Kwok, SK; Park, SH, 2015) |
| "To assess the effectiveness and safety of a protocol using medium doses of prednisone to treat lupus nephritis." | 3.80 | Prednisone in lupus nephritis: how much is enough? ( Danza, A; Delgado, S; Garcia, M; Khamashta, M; Perales, I; Ruiz-Irastorza, G; Villar, I, 2014) |
| " In the univariate analysis, it was associated with age, longer disease duration, antiphospholipid syndrome (APS), higher maximum daily oral prednisolone dose (mg/day), lower mean C3 and C4, higher chronicity index and global sclerosis on renal biopsies (p < 0." | 3.80 | A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis. ( Ghafor, AH; Kong, NC; Said, MS; Shaharir, SS, 2014) |
| "A 30 year old lady patient of SLE on steroid and hydroxychloroquine therapy presented with lupus nephritis and later developed cardiac symptoms." | 3.79 | Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing. ( Bichle, LS; Khubchandani, SR, 2013) |
| "To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients." | 3.75 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. ( Alarcón, GS; Bastian, HM; Danila, MI; McGwin, G; Pons-Estel, GJ; Reveille, JD; Vilá, LM; Zhang, J, 2009) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent used to treat mucocutaneous, musculoskeletal, constitutional manifestations of systemic lupus erythematosus (SLE)." | 3.30 | Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. ( Abdelnabi, HH; Dawoud, HE; El-Shahaby, WA; Elrifaey, SM; Gheet, FS, 2023) |
| "In the treatment of lupus nephritis, conservative therapeutic measures for nephroprotection play a crucial role in renal prognosis." | 3.01 | [What is proven in the treatment of systemic lupus erythematosus?] ( Gödecke, V; Witte, T, 2023) |
| "Eleven children with various forms of lupus nephritis were treated with oral MMF at a mean dose of 22 mg/kg/day (range 17-42) for a mean of 9." | 2.70 | Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. ( Bartosh, S; Buratti, S; Reiff, A; Spencer, CH; Szer, IS, 2001) |
| "Hydroxychloroquine (HCQ) is a commonly used drug for the treatment of systemic lupus erythematosus (SLE)." | 2.58 | Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. ( Ai-Hwiesh, AK; Al-Otaibi, K; El-Solia, A, 2018) |
| "The baseline Systemic Lupus Erythematosus Disease Activity Index score was 0 in 215 patients (52." | 1.91 | Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study. ( Duarte-Rey, C; Gaviria-Mendoza, A; González-Rangel, A; Machado-Alba, JE; Machado-Duque, ME, 2023) |
| "The rarity of the coexistence of LET and lupus nephritis as the initial manifestation of SLE, especially in the North African population, underscores the need for further research to elucidate the immunopathogenic mechanisms and prognostic factors associated with this association." | 1.91 | Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report. ( Abderrahim, E; Badrouchi, S; Ben Hamida, F; Gorsane, I; Hajji, M; Litaiem, N; Rammeh, S, 2023) |
| "Prognosis of lupus nephritis (LN) among patients of African descent living in Europe has been understudied." | 1.72 | Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe. ( Costedoat-Chalumeau, N; Enfrein, A; Houssiau, F; Karras, A; Le Guern, V; Pirson, V; Tamirou, F, 2022) |
| "Proteinuria is one of the most typical manifestations of kidney involvement in Systemic Lupus Erythematosus (SLE)." | 1.62 | "Protenuria in SLE: Is it always lupus?" ( Alessandri, C; Celia, AI; Cerbelli, B; Conti, F; d'Amati, G; Diomedi-Camassei, F; Leuzzi, V; Priori, R; Scrivo, R, 2021) |
| "Lupus nephritis was present in 20." | 1.62 | Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. ( Barros, T; Braga, A; Braga, J; Carvalheira, G; Faria, R; Farinha, F; Marinho, A; Neves, E; Rocha, G; Vasconcelos, C, 2021) |
| "A history of lupus nephritis was noted in 29/121 (24%) patients." | 1.56 | Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists. ( Bhat, V; Haridas, V; Janardana, R; Jois, R; Pinto, B; Priya, V; Rao, VK; Shobha, V; Singh, Y; Srikantiah, C, 2020) |
| "At the last documented visit post-ESRD, 42/59 (71%) patients had one or more clinical or serological markers of lupus activity; only 17/59 (29%) patients achieved clinical and serological remission." | 1.56 | Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. ( Broder, A; Dobrowolski, C; Goilav, B; Londono Jimenez, A; Mowrey, WB; Salgado Guerrero, M; Wang, S, 2020) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| "However, the effect of HCQ on UC-MSCs in lupus nephritis (LN) has not been investigated." | 1.48 | Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. ( Chen, Q; Han, X; Kuang, S; Liao, X; Luan, Y; Ma, J; Mai, S; Tian, X; Wei, Y; Wu, Y; Yang, J; Yang, Y; Zou, L, 2018) |
| "Hydroxychloroquine (HCQ) is a recommended drug in systemic lupus erythematosus (SLE)." | 1.48 | Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? ( Alexander, S; Ashby, D; Cairns, TD; Chusney, G; Cunha, C; Lee, J; Lightstone, L, 2018) |
| "To examine the epidemiology of serious infections, a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE), in a nationwide cohort of SLE and lupus nephritis (LN) patients." | 1.42 | Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. ( Costenbader, KH; Feldman, CH; Franklin, JM; Hiraki, LT; Kim, SC; Marty, FM; Winkelmayer, WC, 2015) |
| "She also had developed anasarca two years prior to presentation." | 1.39 | Systemic lupus erythematosus and granulomatous lymphadenopathy. ( Dhakal, AK; Shah, SC; Shakya, A; Shakya, H; Shiva, RK; Shrestha, D, 2013) |
| "Bullous systemic lupus erythematosus (SLE) is a kind of LE-non-specific bullous skin disease that is rarely induced by a medication." | 1.38 | Methimazole-induced bullous systemic lupus erythematosus: a case report. ( Byun, HJ; Cho, KH; Lee, EB; Seo, JY, 2012) |
| "Few studies have examined thrombosis in systemic lupus erythematosus (SLE), none have included Asian-Americans, and most have had small sample sizes." | 1.35 | Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. ( Cleveland, CM; Criswell, LA; Kaiser, R, 2009) |
| "Systemic lupus erythematosus is a chronic autoimmune disease of unknown etiology with multisystem involvement." | 1.32 | Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. ( Lindsley, CB; Samad, AS, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.35) | 18.7374 |
| 1990's | 2 (2.70) | 18.2507 |
| 2000's | 13 (17.57) | 29.6817 |
| 2010's | 32 (43.24) | 24.3611 |
| 2020's | 26 (35.14) | 2.80 |
| Authors | Studies |
|---|---|
| Braga, A | 1 |
| Barros, T | 1 |
| Faria, R | 1 |
| Marinho, A | 1 |
| Carvalheira, G | 1 |
| Rocha, G | 1 |
| Farinha, F | 1 |
| Neves, E | 1 |
| Vasconcelos, C | 2 |
| Braga, J | 2 |
| Yang, JX | 1 |
| Williamson, KA | 1 |
| Duarte-García, A | 1 |
| Anders, HJ | 2 |
| Loutan, J | 1 |
| Bruchfeld, A | 1 |
| Fernández-Juárez, GM | 1 |
| Floege, J | 2 |
| Goumenos, D | 1 |
| Turkmen, K | 1 |
| van Kooten, C | 1 |
| Frangou, E | 2 |
| Stevens, KI | 1 |
| Kronbichler, A | 1 |
| Segelmark, M | 1 |
| Tesar, V | 3 |
| An, N | 1 |
| Yang, C | 1 |
| Wu, HL | 1 |
| Guo, Y | 1 |
| Huang, XJ | 1 |
| Huang, TS | 1 |
| Wu, ZH | 1 |
| Xue, J | 1 |
| Chen, RH | 1 |
| Li, ZH | 1 |
| Pan, QJ | 1 |
| Liu, HF | 1 |
| Balevic, SJ | 1 |
| Weiner, D | 1 |
| Clowse, MEB | 1 |
| Eudy, AM | 1 |
| Maharaj, AR | 1 |
| Hornik, CP | 1 |
| Cohen-Wolkowiez, M | 1 |
| Gonzalez, D | 1 |
| Arbitman, L | 1 |
| Furie, R | 1 |
| Vashistha, H | 1 |
| Mucke, J | 1 |
| Schneider, M | 3 |
| Enfrein, A | 1 |
| Pirson, V | 1 |
| Le Guern, V | 1 |
| Karras, A | 2 |
| Tamirou, F | 1 |
| Costedoat-Chalumeau, N | 1 |
| Houssiau, F | 1 |
| Gheet, FS | 1 |
| Dawoud, HE | 1 |
| El-Shahaby, WA | 1 |
| Elrifaey, SM | 1 |
| Abdelnabi, HH | 1 |
| Machado-Alba, JE | 1 |
| Machado-Duque, ME | 1 |
| Gaviria-Mendoza, A | 1 |
| Duarte-Rey, C | 1 |
| González-Rangel, A | 1 |
| Hajji, M | 1 |
| Gorsane, I | 1 |
| Badrouchi, S | 1 |
| Litaiem, N | 1 |
| Rammeh, S | 1 |
| Ben Hamida, F | 1 |
| Abderrahim, E | 1 |
| Rao, IR | 1 |
| Kolakemar, A | 1 |
| Shenoy, SV | 1 |
| Prabhu, RA | 1 |
| Nagaraju, SP | 1 |
| Rangaswamy, D | 1 |
| Bhojaraja, MV | 1 |
| Gödecke, V | 1 |
| Witte, T | 1 |
| Rowane, M | 1 |
| Schend, J | 1 |
| Patel, J | 1 |
| Hostoffer, R | 1 |
| Pedrosa, TN | 1 |
| Pasoto, SG | 2 |
| Aikawa, NE | 2 |
| Yuki, EF | 1 |
| Borba, EF | 2 |
| Filho, JCF | 1 |
| Carricondo, PC | 1 |
| Zanetti, CB | 2 |
| Conde, PG | 1 |
| Duarte, NJ | 1 |
| Fontoura, N | 1 |
| Romano, P | 1 |
| Carvalho, VM | 1 |
| Silva, CA | 2 |
| Bonfa, E | 2 |
| Parikh, SV | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Rovin, BH | 1 |
| Fanouriakis, A | 3 |
| Kostopoulou, M | 2 |
| Cheema, K | 1 |
| Aringer, M | 3 |
| Bajema, I | 2 |
| Boletis, J | 3 |
| Houssiau, FA | 3 |
| Hollis, J | 1 |
| Marchiori, F | 1 |
| Marks, SD | 2 |
| Moroni, G | 2 |
| Mosca, M | 2 |
| Parodis, I | 1 |
| Praga, M | 2 |
| Smolen, JS | 1 |
| Trachana, M | 1 |
| van Vollenhoven, RF | 2 |
| Voskuyl, AE | 1 |
| Teng, YKO | 2 |
| van Leew, B | 1 |
| Bertsias, G | 3 |
| Jayne, D | 3 |
| Boumpas, DT | 4 |
| Wu, CY | 1 |
| Tan, M | 1 |
| Huang, JY | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Janardana, R | 1 |
| Haridas, V | 1 |
| Priya, V | 1 |
| Bhat, V | 1 |
| Singh, Y | 1 |
| Rao, VK | 1 |
| Jois, R | 1 |
| Srikantiah, C | 1 |
| Pinto, B | 1 |
| Shobha, V | 1 |
| Kadosawa, K | 1 |
| Morikawa, T | 1 |
| Konishi, Y | 1 |
| Tziolos, N | 1 |
| Salgado Guerrero, M | 1 |
| Londono Jimenez, A | 1 |
| Dobrowolski, C | 1 |
| Mowrey, WB | 1 |
| Goilav, B | 1 |
| Wang, S | 1 |
| Broder, A | 1 |
| Fayed, A | 1 |
| El Menyawi, MM | 1 |
| Ghanema, M | 1 |
| Shaker, O | 1 |
| Elgohary, R | 1 |
| Celia, AI | 1 |
| Priori, R | 1 |
| Cerbelli, B | 1 |
| Diomedi-Camassei, F | 1 |
| Leuzzi, V | 1 |
| Scrivo, R | 1 |
| Alessandri, C | 1 |
| d'Amati, G | 1 |
| Conti, F | 1 |
| Pedrosa, T | 1 |
| Kupa, LVK | 1 |
| Vendramini, MBG | 1 |
| Chavatza, K | 1 |
| Nikolopoulos, D | 1 |
| Gioti, O | 1 |
| Togia, K | 1 |
| Andreoli, L | 1 |
| Doria, A | 2 |
| Svenungsson, E | 1 |
| Tincani, A | 1 |
| Mok, CC | 1 |
| Ho, LY | 1 |
| Tse, SM | 1 |
| Chan, KL | 1 |
| Bojic, M | 1 |
| Kozakowski, N | 1 |
| Bécède, M | 1 |
| Kerschbaumer, A | 1 |
| Bobacz, K | 1 |
| Cunha, C | 1 |
| Alexander, S | 1 |
| Ashby, D | 1 |
| Lee, J | 1 |
| Chusney, G | 1 |
| Cairns, TD | 1 |
| Lightstone, L | 2 |
| Mai, S | 1 |
| Zou, L | 1 |
| Tian, X | 1 |
| Liao, X | 1 |
| Luan, Y | 1 |
| Han, X | 1 |
| Wei, Y | 1 |
| Wu, Y | 1 |
| Kuang, S | 1 |
| Yang, Y | 1 |
| Ma, J | 1 |
| Chen, Q | 1 |
| Yang, J | 1 |
| El-Solia, A | 1 |
| Al-Otaibi, K | 1 |
| Ai-Hwiesh, AK | 1 |
| Karasawa, K | 1 |
| Uchida, K | 1 |
| Takabe, T | 1 |
| Moriyama, T | 1 |
| Nitta, K | 1 |
| Keeling, SO | 1 |
| Bissonauth, A | 1 |
| Bernatsky, S | 2 |
| Vandermeer, B | 1 |
| Fortin, PR | 1 |
| Gladman, DD | 1 |
| Peschken, C | 1 |
| Urowitz, MB | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 1 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| Rothwell, R | 1 |
| Oliveira, M | 1 |
| Rodrigues, D | 1 |
| Fonseca, S | 1 |
| Varandas, R | 1 |
| Ribeiro, L | 1 |
| Seo, MR | 1 |
| Chae, J | 1 |
| Kim, YM | 1 |
| Cha, HS | 1 |
| Choi, SJ | 1 |
| Oh, S | 1 |
| Roh, CR | 1 |
| Wakiya, R | 1 |
| Kameda, T | 1 |
| Ueeda, K | 1 |
| Nakashima, S | 1 |
| Shimada, H | 1 |
| Mansour, MF | 1 |
| Kato, M | 1 |
| Miyagi, T | 1 |
| Miyatake, N | 1 |
| Kadowaki, N | 1 |
| Dobashi, H | 1 |
| Serre, J | 1 |
| Buob, D | 1 |
| Boffa, JJ | 1 |
| Khubchandani, SR | 1 |
| Bichle, LS | 1 |
| Ruiz-Irastorza, G | 2 |
| Danza, A | 2 |
| Khamashta, M | 2 |
| Fangtham, M | 1 |
| Petri, M | 2 |
| Perales, I | 1 |
| Villar, I | 1 |
| Garcia, M | 1 |
| Delgado, S | 1 |
| Shrestha, D | 1 |
| Dhakal, AK | 1 |
| Shiva, RK | 1 |
| Shakya, A | 1 |
| Shah, SC | 1 |
| Shakya, H | 1 |
| Shaharir, SS | 1 |
| Ghafor, AH | 1 |
| Said, MS | 1 |
| Kong, NC | 1 |
| Peart, E | 1 |
| Clowse, ME | 1 |
| Pokroy-Shapira, E | 1 |
| Gelernter, I | 1 |
| Molad, Y | 1 |
| Koh, JH | 1 |
| Ko, HS | 1 |
| Kwok, SK | 1 |
| Ju, JH | 1 |
| Park, SH | 1 |
| Feldman, CH | 1 |
| Hiraki, LT | 1 |
| Winkelmayer, WC | 1 |
| Marty, FM | 1 |
| Franklin, JM | 1 |
| Kim, SC | 1 |
| Costenbader, KH | 2 |
| Tedeschi, SK | 1 |
| Massarotti, E | 1 |
| Guan, H | 1 |
| Fine, A | 1 |
| Bermas, BL | 1 |
| Basaran, O | 1 |
| Aydın, F | 1 |
| Celikel, BA | 1 |
| Uncu, N | 1 |
| Cakar, N | 1 |
| Staveri, C | 1 |
| Karokis, D | 1 |
| Liossis, SC | 1 |
| Kaiser, R | 1 |
| Cleveland, CM | 1 |
| Criswell, LA | 1 |
| Pons-Estel, GJ | 1 |
| Alarcón, GS | 1 |
| McGwin, G | 1 |
| Danila, MI | 1 |
| Zhang, J | 1 |
| Bastian, HM | 1 |
| Reveille, JD | 1 |
| Vilá, LM | 1 |
| Vlad, SC | 1 |
| Vinet, E | 1 |
| Suissa, S | 1 |
| Bader-Meunier, B | 1 |
| Madhok, R | 1 |
| Wu, O | 1 |
| Samson, M | 1 |
| Audia, S | 1 |
| Leguy, V | 1 |
| Berthier, S | 1 |
| Janikashvili, N | 1 |
| Martin, L | 1 |
| Bonnotte, B | 1 |
| Lorcerie, B | 1 |
| Zheng, ZH | 1 |
| Zhang, LJ | 1 |
| Liu, WX | 1 |
| Lei, YS | 1 |
| Xing, GL | 1 |
| Zhang, JJ | 1 |
| Quan, SX | 1 |
| Liu, D | 1 |
| Hu, DS | 1 |
| Li, LL | 1 |
| Liu, ZS | 1 |
| Seo, JY | 1 |
| Byun, HJ | 1 |
| Cho, KH | 1 |
| Lee, EB | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Bertsias, GK | 1 |
| Tektonidou, M | 1 |
| Amoura, Z | 1 |
| Berden, JH | 1 |
| Cervera, R | 1 |
| Dörner, T | 1 |
| Ferrario, F | 1 |
| Ioannidis, JP | 1 |
| Isenberg, DA | 1 |
| Kallenberg, CG | 1 |
| Martini, A | 1 |
| Neumann, I | 1 |
| Starra, A | 1 |
| Zakharova, H | 1 |
| Haubitz, M | 1 |
| Gordon, C | 1 |
| Zdrojewski, Z | 1 |
| Samad, AS | 1 |
| Lindsley, CB | 1 |
| Wang, LC | 1 |
| Tsai, WY | 1 |
| Yang, YH | 1 |
| Chiang, BL | 1 |
| Barber, CE | 1 |
| Geldenhuys, L | 1 |
| Hanly, JG | 1 |
| Kasitanon, N | 1 |
| Fine, DM | 1 |
| Haas, M | 1 |
| Magder, LS | 1 |
| Mittal, BV | 1 |
| Pendse, S | 1 |
| Rennke, HG | 1 |
| Singh, AK | 1 |
| Sallmann, S | 1 |
| Fiebig, B | 1 |
| Hedrich, CM | 1 |
| Heubner, G | 1 |
| Gahr, M | 1 |
| Sisó, A | 1 |
| Ramos-Casals, M | 1 |
| Bové, A | 1 |
| Brito-Zerón, P | 1 |
| Soria, N | 1 |
| Muñoz, S | 1 |
| Testi, A | 1 |
| Plaza, J | 1 |
| Sentís, J | 1 |
| Coca, A | 1 |
| Walsh, DS | 1 |
| Farley, MF | 1 |
| Beard, JS | 1 |
| Sau, P | 1 |
| Tesar, J | 1 |
| James, WD | 1 |
| Fagundus, DM | 1 |
| Leroy, EC | 1 |
| Buratti, S | 1 |
| Szer, IS | 1 |
| Spencer, CH | 1 |
| Bartosh, S | 1 |
| Reiff, A | 1 |
| Pourrat, JP | 1 |
| Fournie, GJ | 1 |
| Fournie, B | 1 |
| Mignon-Conte, M | 1 |
| Conte, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Hydroxychloroquine Blood Levels in Patients With Primary Sjögren Syndrome and Possible Correlation With the Disease Activity[NCT04546542] | 75 participants (Anticipated) | Observational | 2020-10-01 | Active, not recruiting | |||
| Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study[NCT05207358] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis[NCT04146220] | Phase 4 | 32 participants (Actual) | Interventional | 2018-07-16 | Completed | ||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
15 reviews available for hydroxychloroquine and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
B cell-targeted therapies in systemic lupus erythematosus.
Topics: Autoantibodies; B-Lymphocytes; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lu | 2022 |
Hydroxychloroquine in nephrology: current status and future directions.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Ne | 2023 |
[What is proven in the treatment of systemic lupus erythematosus?]
Topics: Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis | 2023 |
Update on Lupus Nephritis: Core Curriculum 2020.
Topics: Adaptive Immunity; Adrenal Cortex Hormones; Age Distribution; Autoantibodies; Autoimmunity; Biopsy; | 2020 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hypoglycemia; Lupus Nephritis; Peri | 2018 |
Recent Advances in Treatment Strategies for Lupus Nephritis.
Topics: Antihypertensive Agents; Antirheumatic Agents; Cyclophosphamide; Drug Therapy, Combination; Glucocor | 2018 |
[Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; | 2013 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Female; Heart Block; Humans; Hydrox | 2014 |
Systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Humans; Hydroxychloro | 2009 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
[Modern methods for diagnosis and therapy of lupus nephritis].
Topics: Biological Therapy; Humans; Hydroxychloroquine; Immunosuppression Therapy; Lupus Nephritis | 2011 |
Methimazole-induced lupus erythematosus: a case report.
Topics: Adolescent; Antibodies; Antibodies, Antinuclear; DNA; Female; Glucocorticoids; Goiter; Humans; Hydro | 2003 |
[Systemic lupus erythematosus in children and adolescents].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Child; Diagnosis, Diff | 2006 |
3 trials available for hydroxychloroquine and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
Topics: Child; Double-Blind Method; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosu | 2023 |
Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Pr | 2021 |
Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therap | 2001 |
56 other studies available for hydroxychloroquine and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newbor | 2021 |
75-Year-Old Man With Fever and Malaise.
Topics: Acute Kidney Injury; Aged; Antirheumatic Agents; Diagnosis, Differential; Humans; Hydroxychloroquine | 2021 |
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021.
Topics: Biopsy; Child; Female; Glomerulonephritis, Membranous; Humans; Hydroxychloroquine; Immunosuppressive | 2023 |
Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis.
Topics: Acute Kidney Injury; Animals; Female; Hydroxychloroquine; Kidney; Lupus Nephritis; Mice; Mice, Inbre | 2022 |
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Infant, Newborn; Lupus Erythematosus, Syst | 2022 |
[Lupus nephritis].
Topics: Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Lupus Erythem | 2023 |
Worse long-term renal outcome of lupus nephritis patients of African descent living in Europe.
Topics: Creatinine; Humans; Hydroxychloroquine; Kidney; Lupus Nephritis; Renal Insufficiency, Chronic; Retro | 2022 |
Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study.
Topics: Adult; Colombia; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; | 2023 |
Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report.
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, Discoid; Lupus Erythematosus | 2023 |
Rapid desensitization of hydroxychloroquine.
Topics: Anti-Inflammatory Agents; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hydro | 2020 |
Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
Topics: Adult; Antirheumatic Agents; Brazil; Case-Control Studies; Chromatography, Liquid; Disease Progressi | 2020 |
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Topics: Antirheumatic Agents; Azathioprine; Calcineurin Inhibitors; Drug Therapy, Combination; Europe; Glome | 2020 |
Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Renal Insufficiency, Chr | 2022 |
Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hydroxychloroquine; India; Infant, Newborn; Lupus Eryt | 2020 |
Zebra bodies without Fabry disease or hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Fabry Disease; Humans; Hydroxychloroquine | 2021 |
Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
Topics: Adult; Autoantibodies; Biomarkers; Complement System Proteins; Disease Progression; DNA; Enzyme Inhi | 2020 |
Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Case-Control Studies; Complement | 2020 |
"Protenuria in SLE: Is it always lupus?"
Topics: Antirheumatic Agents; Biopsy; Diagnosis, Differential; Enzyme Replacement Therapy; Fabry Disease; Fe | 2021 |
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Aspirin; Drug Tapering; Europe; Fema | 2021 |
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; China; Databases, Factual; Female; Glucocorticoids; Human | 2017 |
The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus.
Topics: Adult; Biopsy; Cyclophosphamide; Female; Glomerulonephritis, Membranoproliferative; Humans; Hydroxyc | 2017 |
Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Disease Progression; Drug Monitoring; Female; Humans; | 2018 |
Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice.
Topics: Animals; Antibodies; B-Lymphocytes; Cell Movement; Cells, Cultured; Female; Humans; Hydroxychloroqui | 2018 |
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
Topics: Adult; Antimalarials; Antirheumatic Agents; Biological Products; Canada; Cardiovascular Diseases; Fe | 2018 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Choroid thickness profile in patients with lupus nephritis.
Topics: Adult; Analysis of Variance; Case-Control Studies; Choroid; Cross-Sectional Studies; Female; Humans; | 2019 |
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Topics: Adult; Antirheumatic Agents; Female; Gestational Age; Humans; Hydroxychloroquine; Infant, Newborn; L | 2019 |
Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Biomarkers; Calgranulin A; Calgranulin B; Female; Humans; Hydroxychloro | 2019 |
Hydroxychloroquine-induced podocytopathy mimicking Fabry disease.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Fabry Disease; Female; Humans; Hydroxychloroqu | 2019 |
Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing.
Topics: Adult; Antirheumatic Agents; Cyclophosphamide; Female; Glucocorticoids; Humans; Hydroxychloroquine; | 2013 |
Prednisone in lupus nephritis: how much is enough?
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2014 |
Systemic lupus erythematosus and granulomatous lymphadenopathy.
Topics: Antibodies, Antinuclear; Child; Connective Tissue Diseases; Diagnosis, Differential; Disease Progres | 2013 |
A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
Topics: Adult; Antiphospholipid Syndrome; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human | 2014 |
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydro | 2014 |
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Apgar Score; Female; Fetal Growth Retardation; Follow-Up Studies; Human | 2015 |
Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Female; Glucocor | 2015 |
Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Hydroxychloroquine; Logistic Models; Lupu | 2015 |
Coexistence of systemic lupus erythematosus and familial Mediterranean fever in a pediatric patient.
Topics: Adolescent; Colchicine; Cyclophosphamide; Familial Mediterranean Fever; Female; Humans; Hydroxychlor | 2016 |
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Disease Progression; Drug Therapy, Combinati | 2017 |
Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; California; Child; Female; Humans; Hydroxyc | 2009 |
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.
Topics: Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Disease Progression; Female; | 2009 |
Protective effect of hydroxychloroquine on renal damage may be biased: comment on the article by Pons-Estel et al.
Topics: Bias; Enzyme Inhibitors; Humans; Hydroxychloroquine; Kidney; Lupus Nephritis; Risk Factors | 2009 |
Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel et al.
Topics: Bias; Enzyme Inhibitors; Humans; Hydroxychloroquine; Kidney; Lupus Nephritis; Proportional Hazards M | 2009 |
[Childhood onset systemic lupus erythematosus: how does it must be treated in 2010?].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Child; Evide | 2010 |
Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange.
Topics: Acute Kidney Injury; Adult; Biopsy; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combi | 2012 |
Predictors of survival in Chinese patients with lupus nephritis.
Topics: Adolescent; Adult; Age of Onset; Aged; Asian People; Child; China; Cohort Studies; Creatinine; Femal | 2012 |
Methimazole-induced bullous systemic lupus erythematosus: a case report.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Antithyroid Agents; Blister; Drug Therapy, Co | 2012 |
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
Topics: Adult; Azathioprine; Biopsy; Child; Cyclophosphamide; Disease Management; Dose-Response Relationship | 2012 |
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
Topics: Adolescent; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Hemorrhage; H | 2003 |
Sustained remission of lupus nephritis.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Azathioprine; Creatinine; Cyclophosphamide; Di | 2006 |
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Hematuria in a patient with class IV lupus nephritis.
Topics: Antihypertensive Agents; Biopsy; Cyclophosphamide; El Salvador; Female; Follow-Up Studies; Glomerula | 2006 |
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Topics: Adolescent; Adult; Aged; Antimalarials; Biopsy; Child; Chloroquine; Disease Progression; Female; Fol | 2008 |
Systemic lupus erythematosus: nephritis, dilated cardiomyopathy, and extensive cutaneous depigmentation responsive to hydroxychloroquine.
Topics: Adult; Cardiomyopathy, Dilated; Humans; Hydroxychloroquine; Hypopigmentation; Lupus Erythematosus, S | 1995 |
Lupus and its management.
Topics: Adolescent; Antibiotics, Antineoplastic; Autoantibodies; Azathioprine; Cyclophosphamide; Dose-Respon | 1993 |
[Treatment of lupus nephropathies without corticoids].
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Indomethaci | 1986 |